Premium
Feasibility of dasatinib in children and adolescents with new or recurrent central nervous system germinoma
Author(s) -
Osorio Diana S.,
Finlay Jonathan L.,
Dhall Girish,
Goldman Stewart,
Eisenstat David,
Brown Robert J.
Publication year - 2013
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24567
Subject(s) - dasatinib , medicine , germinoma , germ cell tumors , central nervous system , tolerability , oncology , tyrosine kinase inhibitor , tyrosine kinase , cancer , chemotherapy , receptor , adverse effect
Germinomas and embryonal carcinomas are central nervous system (CNS) germ cell tumors (GCT) that may overexpress the proto‐oncogene c‐KIT , a receptor tyrosine kinase, of which dasatinib is a potent inhibitor. This retrospective review presents the feasibility and tolerability of dasatinib administration in select patients with CNS germinoma. Between November 2008 and April 2010, six patients with newly diagnosed (n = 3) or recurrent (n = 3) CNS GCT were treated in an effort to avoid irradiation and/or delay recurrence. The daily doses administered were 100–170 mg/m 2 with mostly grade 1–2 toxicities. Dasatinib may play a role in future treatment strategies for CNS GCT. Pediatr Blood Cancer 2013;60:E100–E102. © 2013 Wiley Periodicals, Inc.